ArticleBiosensors2021
Clinical Application of the Novel Cell-Based Biosensor for the Ultra-Rapid Detection of the SARS-CoV-2 S1 Spike Protein Antigen: A Practical Approach.
Article in Biosensors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- The Role of Pharmacies in Providing Point-of-Care Services in the Era of Digital Health and Artificial Intelligence: An Updated Review of Technologies, Regulation and Socioeconomic Considerations.Healthcare (Basel, Switzerland) · 2026Review
- AlHeliyon · 2024Article
- Advances in nanobiosensors during the COVID-19 pandemic and future perspectives for the post-COVID era.Nano convergence · 2024Review
- A Systematic Review and Meta-Analysis Comparing the Diagnostic Accuracy Tests of COVID-19.Diagnostics (Basel, Switzerland) · 2023Review
- Advancement in COVID-19 detection using nanomaterial-based biosensors.Exploration (Beijing, China) · 2023Review
- Electrochemical Capillary Driven Immunoassay for Detection of SARS-CoV-2.ACS measurement science au · 2022Article
- Towards Label-free detection of viral disease agents through their cell surface proteins: Rapid screening SARS-CoV-2 in biological specimens.SLAS discovery : advancing life sciences R & D · 2022Article
- Cell-Based Platform for Antigen Testing and Its Application for SARS-CoV-2 Infection.Microbiology spectrum · 2022Article
- A Biosensor Platform for Point-of-Care SARS-CoV-2 Screening.Biosensors · 2022Article
- Development and evaluation of time-resolved fluorescent immunochromatographic assay for quantitative detection of SARS-CoV-2 spike antigen.Journal of clinical laboratory analysis · 2022Article
- Review
- ACE2-based capacitance sensor for rapid native SARS-CoV-2 detection in biological fluids and its correlation with real-time PCR.Biosensors & bioelectronics · 2022Article
- COVID-19 diagnosis by SARS-CoV-2 Spike protein detection in saliva using an ultrasensitive magneto-assay based on disposable electrochemical sensor.Sensors and actuators. B, Chemical · 2022Article
- A review on corona virus disease 2019 (COVID-19): current progress, clinical features and bioanalytical diagnostic methods.Mikrochimica acta · 2022Review
- Highly sensitive and ultra-rapid antigen-based detection of SARS-CoV-2 using nanomechanical sensor platform.Biosensors & bioelectronics · 2022Article
- Investigation of the Morphology and Electrical Properties of Graphene Used in the Development of Biosensors for Detection of Influenza Viruses.Biosensors · 2021Article
- Recent findings and applications of biomedical engineering for COVID-19 diagnosis: a critical review.Bioengineered · 2021Review
- Polyelectrolyte Multilayers: An Overview on Fabrication, Properties, and Biomedical and Environmental Applications.Materials (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The availability of antigen tests for SARS-CoV-2 represents a major step for the mass surveillance of the incidence of infection, especially regarding COVID-19 asymptomatic and/or early-stage patients. Recently, we reported the development of a Bioelectric Recognition Assay-based biosensor able to detect the SARS-CoV-2 S1 spike protein expressed on the surface of the virus in just three minutes, with high sensitivity and selectivity. The working principle was established by measuring the change of the electric potential of membrane-engineered mammalian cells bearing the human chimeric spike S1 antibody after attachment of the respective viral protein. In the present study, we applied the novel biosensor to patient-derived nasopharyngeal samples in a clinical set-up, with absolutely no sample pretreatment. More importantly, membrane-engineered cells were pre-immobilized in a proprietary biomatrix, thus enabling their long-term preservation prior to use as well as significantly increasing their ease-of-handle as test consumables. The plug-and-apply novel biosensor was able to detect the virus in positive samples with a 92.8% success rate compared to RT-PCR. No false negative results were recorded. These findings demonstrate the potential applicability of the biosensor for the early, routine mass screening of SARS-CoV-2 on a scale not yet realized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.